OakChart

Artelo Biosciences Inc

ARTLHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 8:27 AM ET

2.23+0.09 (4.10%)
2026-11-11 14:40 CET
Market cap
1.17 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-12.67 USD m
Free cash flow, TTM
-12.80 USD m
EPS diluted, TTM
-206.84
P/E
-
Compare

Price

ARTL against its 20, 50 and 200-day averages
2050200earnings
0.0025.0050.0075.0012.6M25.1MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ARTLclose 2.2320-day 2.3550-day 3.64200-day 19.992.23

98.8% under 179.19 on 27 Mar 2026. Last 15 sessions, 39.0% high to low

Profile

ARTL
52-week range, 0% of the way up
1.91179.19

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Employees7
IPONov 14, 2017
Beta-0.01
ATR, 14d0.34
Rel volume0.12
Short float5.04%
Insider own0.06%
Inst own2.50%

Snapshot

6 groups

Valuation

Index-
Market Cap1.22M
Enterprise Value-2.93M
Income-12.67M
Sales0.00M
Book/sh10.74
Cash/sh7.69
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees7
IPONov 14, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.21
P/C0.29
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio3.00
Current Ratio3.00
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-206.84
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y16.31% 35.60%
Sales past 3/5Y- -
EPS Y/Y TTM59.79%
Sales Y/Y TTM-
EPS Q/Q94.68%
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own0.06%
Insider Trans0.00%
Inst Own2.50%
Inst Trans-3.84%
ROA-234.30%
ROE-705.71%
ROIC-253.22%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-5.00%
SMA50-38.74%
SMA200-88.85%
Trades-

Technical

Shs Outstand0.55M
Shs Float0.55M
Short Float5.04%
Short Ratio0.06
Short Interest0.03M
52W High179.19 -98.76%
52W Low1.91 16.75%
Volatility14.94% 9.27%
ATR (14)0.34
RSI (14)37.89
Beta-0.01
Rel Volume0.12
Avg Volume480.86K
Volume2,870

Performance

Perf Week-1.76%
Perf Month-25.17%
Perf Quarter-67.34%
Perf Half Y-89.27%
Perf YTD-93.23%
Perf Year-95.79%
Perf 3Y-98.92%
Perf 5Y-99.89%
Perf 10Y-
Recom3.00
Target Price486.00
Prev Close2.14
Price2.23
Change %4.10%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Jul 08, 2025UpgradeDD. Boral CapitalHold → Buy$20+796.9%
Feb 12, 2021InitiatedLLadenburg ThalmannBuy$7+213.9%

Peers

Mkt cap
TickerCompanyMkt cap
SKYESkye Bioscience Inc3.98M
LEXXLexaria Bioscience Corp9.86M
SPRCSciSparc Ltd0.83M
CRBPCorbus Pharmaceuticals Holdings Inc77.36M
IGCIGC Pharma Inc22.74M
CMNDClearmind Medicine Inc2.58M
ENVBEnveric Biosciences Inc6.76M
SILOSILO Pharma Inc2.90M
PCSAProcessa Pharmaceuticals Inc5.23M
ABVCABVC BioPharma Inc26.43M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.61B

News

latest 14 of 206
  • Artelo Biosciences to Present ART27.13 Data Demonstrating Potential to Treat Chemotherapy-Induced Neuropathic Pain at the IASP 2026 World Congress on Pain (GlobeNewswire)
  • Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain (GlobeNewswire) -13.73%
  • Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform (GlobeNewswire)
  • Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings (GlobeNewswire) +76.14%
  • Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity (GlobeNewswire) -29.78%
  • Loading…
  • Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Artelo Biosciences Announces Reverse Stock Split (GlobeNewswire) -6.98%
  • Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 (GlobeNewswire)
  • Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies (GlobeNewswire) -8.76%
  • Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results (GlobeNewswire)
  • Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma (GlobeNewswire)
  • New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy - Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition (GlobeNewswire)
  • Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-8.010--8.0100.00--
2026Q12026-05-14-36.000--36.0240.00--
2025Q42026-02-24-59.940-42.390-55.7190.00-1
2025Q32025-11-12-107.19-22.140-107.040.000.001
2025Q22025-08-13-151.47-113.13-151.510.000.001
2025Q12025-05-13-116.64-21.595-117.120.000.001
2024Q42025-03-03-189.54-70.745-188.950.00-3
2024Q32024-11-12-56.700-128.39-56.8100.000.004
2024Q22024-08-13-121.5-128.51-122.10.000.003
2024Q12024-05-13-126.36-158.76-125.820.000.002
2023Q42024-03-25-160.38-90.185-156.110.000.003
2023Q32023-11-13-134.46-104.77-134.530.000.003
2023Q22023-08-10-90.720-125.55-90.6990.000.002
2023Q12023-05-11-123.12-178.2-122.970.000.002
2022Q42023-03-31-191.16-118.26-189.420.000.003
2026Q3---7.020--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-3,548-3,159-2,430--
2020FY-3,062--3,051--
2021FY-972-947.7-9720.000.00
2022FY-576.72-493.01-576.580.000.00
2023FY-508.68-414.19-508.390.000.00
2024FY-494.1-319.14-493.890.000.00
2025FY-338.04-326.97-338.040.00-
2026FY--88.560---
2027FY--47.520---
2028FY-113.4--99.56
2029FY-271.35--184.73
2030FY-365.58--245.3

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00
2026Q3S2025-11-021000.000.000.00
2026Q3S2025-11-011000.000.000.00
2026Q3S2025-10-311000.000.000.00
2026Q3S2025-10-301000.000.000.00
2026Q3S2025-10-291000.000.000.00
2026Q3S2025-10-281000.000.000.00
2026Q3S2025-10-271000.000.000.00
2026Q3S2025-10-261000.000.000.00
2026Q3S2025-10-251000.000.000.00
2026Q3S2025-10-241000.000.000.00

Estimate history

EPS, annual-8.402-522.936-4457.592-2429.684-3050.816-576.577-508.385-493.891-337.933-206.8367
Period201620172018201920202022202320242025TTM
EPS, quarterly-122.103-56.81-188.95-117.118-151.511-107.039-55.719-36.024-8.054
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201620172018201920202022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0040.0010.0010.0010.0020.0180.020.020.0750.465
Period201620172018201920202022202320242025MRQ
Shares, quarterly0.020.020.020.020.0260.0580.0750.0970.465
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.00-0.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.00-0.000.000.00
Gross Profit0.000.000.000.000.00--0.00-0.00-0.00
Selling, General and Administrative Excl. Other11.0711.4010.119.9310.29-4.693.212.34
Research and Development3.825.425.995.704.32-1.921.091.25
Other Operating Expense0.000.000.000.000.00-0.000.000.00
Operating Income-11.07-11.40-10.11-9.93-10.29--4.69-3.21-2.34
Interest Expense0.340.280.000.000.01-0.000.000.00
Unusual Expense1.321.22-0.28-0.64-0.21--0.03-1.01-
Net Income Before Taxes-12.67-12.88-9.83-9.29-10.08--4.65-2.17-2.34
Income Taxes0.000.000.000.000.00-0.000.000.00
Consolidated Net Income-12.67-12.88-9.83-9.29-10.08--4.65-2.17-2.34
Net Income From Continuing Operations-12.67-12.88-9.83-9.29-10.08--4.65-2.17-2.34
Net Income-12.67-12.88-9.83-9.29-10.08--4.65-2.17-2.34
EPS (Recurring)-38.97-315.52-503.81-532.94-584.86--3,064.34-3,217.43-4,457.58
EPS (Basic, Before Extraordinaries)-206.84-337.93-493.89-508.39-576.58--3,050.82-2,429.68-4,457.59
EPS (Diluted)-206.84-337.93-493.89-508.39-576.58--3,050.82-2,429.68-4,457.59
EBITDA-11.07-11.40-10.11-9.93-10.29--4.69-3.21-2.34
Non-Operating Income (Expense)0.070.020.000.000.00-0.000.030.00
Other After Tax Adjustments0.000.000.000.000.00-0.000.000.00
Stock Option Compensation Expense1.271.140.821.022.46-0.040.050.06
Shares Outstanding0.470.070.020.020.02-0.000.000.00
Market Capitalization1.171.173.484.438.25-4.790.510.51

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.000.00
Selling, General and Administrative Excl. Other2.512.692.793.093.152.383.811.20
Research and Development0.880.770.891.281.871.382.480.33
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.50-2.69-2.79-3.09-3.15-2.38-3.81-1.20
Interest Expense0.010.120.090.110.070.000.000.00
Unusual Expense-0.040.151.30-0.080.000.00-0.03-0.06
Net Income Before Taxes-2.43-2.96-4.17-3.12-3.22-2.37-3.78-1.13
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-2.43-2.96-4.17-3.12-3.22-2.37-3.78-1.13
Net Income From Continuing Operations-2.43-2.96-4.17-3.12-3.22-2.37-3.78-1.13
Net Income-2.43-2.96-4.17-3.12-3.22-2.37-3.78-1.13
EPS (Recurring)-8.15-34.78-43.59-108.84-151.51-117.12-190.14-59.02
EPS (Basic, Before Extraordinaries)-8.05-36.02-55.72-107.04-151.51-117.12-188.95-56.81
EPS (Diluted)-8.05-36.02-55.72-107.04-151.51-117.12-188.95-56.81
EBITDA-2.50-2.69-2.79-3.09-3.15-2.38-3.81-1.20
Non-Operating Income (Expense)0.040.000.020.010.000.010.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.210.260.370.430.150.190.200.21
Shares Outstanding0.470.100.070.060.030.020.020.02
Market Capitalization1.176.642.467.149.352.873.483.62

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments0.602.3410.4317.53-2.144.420.340.57
Short Term Receivables0.000.000.000.00-0.000.010.020.00
Inventories0.000.000.000.00-0.000.000.000.00
Other Current Assets0.100.220.550.79-0.200.010.040.00
Total Current Assets0.702.5610.9818.32-2.344.440.400.57
Net Property, Plant & Equipment0.060.100.020.06-0.000.000.000.00
Total Investments and Advances0.000.000.000.00-0.000.000.000.00
Intangible Assets2.042.042.042.04-2.042.040.000.00
Other Assets0.000.000.000.00-0.000.000.000.00
Total Assets2.804.7013.0420.42-4.386.480.400.57
Short Term Debt Incl. Current Port. of LT Debt0.650.040.020.04-0.000.000.000.00
Accounts Payable3.041.681.240.00-0.000.000.000.00
Other Current Liabilities0.360.060.030.96-0.501.020.530.03
Total Current Liabilities4.041.771.291.00-0.501.020.530.03
Long Term Debt0.030.070.000.02-0.000.000.000.00
Provision for Risks Charges0.000.000.000.00-0.000.000.000.00
Other Liabilities0.000.000.000.00-0.000.000.000.00
Total Liabilities4.071.841.291.02-0.501.020.530.03
Non-Equity Reserves0.000.000.000.00-0.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00-0.000.000.000.00
Common Equity-1.272.8611.7519.40-3.875.46-0.130.54
Total Shareholders Equity-1.272.8611.7519.40-3.875.46-0.130.54
Accumulated Minority Interest0.000.000.000.00-0.000.000.000.00
Total Equity-1.272.8611.7519.40-3.875.46-0.130.54
Total Liabilities & Stockholders Equity2.804.7013.0420.42-4.386.480.400.57
Book Value Per Share-17.01141.06597.001,100.71-1,886.273,957.15-187.39935.05
Tangible Book Value Per Share-44.2840.39493.42985.04-893.442,479.40-187.39935.05
Full-Time Employees7667-3422
Price to Book Ratio0.201.220.300.38-1.243.813.81-
Return on Assets-343.49-110.77-55.51-61.00--85.73-63.15-482.56-81.30
Return on Equity-1,625.11-134.52-59.63-64.13--99.72-81.57-1,143.55-88.46
Return on Invested Capital--335.82-79.04-51.90--120.14-39.77--43.11
Quick Ratio0.171.448.5118.36-4.654.350.7519.51
Current Ratio0.171.448.5118.36-4.654.350.7519.51

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2020FY2019FY2018FY
Net Income-12.85-12.88-9.83-9.29-10.08--4.65-2.17-2.34
Depreciation------0.000.000.00
Other Funds (Non Cash)3.462.610.570.422.29-0.35-0.480.29
Funds from Operations-9.39-10.27-9.26-8.87-7.79--4.31-2.65-2.05
Extraordinary Item0.000.000.000.000.00-0.000.000.00
Changes in Working Capital-3.411.750.910.66-0.22--0.04-0.140.44
Cash from Operating Activities-12.80-8.52-8.35-8.21-8.01--4.35-2.79-1.61
Capital Expenditures0.000.000.000.000.00-0.00-1.50-0.00
Net Assets From Acquisitions0.000.000.000.000.00-0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.00-0.000.000.00
Purchase or Sale of Investments-0.06-0.067.773.512.96-0.000.000.00
Purchase of Investments-0.26-0.25-0.48-13.69-13.22-0.000.000.00
Sale Or Maturity of Investments0.190.198.2517.1916.18-0.000.000.00
Other Uses0.000.000.000.000.00-0.000.000.00
Other Sources0.000.000.000.000.00-0.000.000.00
Cash from Investing Activities-0.06-0.067.773.512.96-0.00-1.50-0.00
Cash Dividends Paid0.000.000.000.000.00-0.000.000.00
Change in Capital Stock15.776.280.110.570.00-1.988.381.39
Repurchase of Common Pref Stock0.000.000.000.000.00--0.000.000.00
Sale of Common Pref Stock15.776.280.110.570.00-1.988.381.39
Proceedsfrom Stock Options15.406.150.110.570.00-1.988.381.39
Issuance or Reduction of Debt, Net-0.810.580.000.000.00-0.000.000.00
Change in Long Term Debt0.000.000.000.000.00-0.000.000.00
Issuance of Long Term Debt0.000.000.000.000.00-0.000.000.00
Reduction of Long Term Debt0.000.000.000.000.00-0.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.000.000.00
Other Financing Activities Uses0.000.000.000.000.00--0.00-0.02-0.02
Cash from Financing Activities14.966.870.110.570.00-1.988.381.39
Exchange Rate Effect-0.02-0.02-0.010.06-0.22-0.080.00-0.01
Net Change in Cash2.08-1.74-0.48-4.07-5.27--2.284.09-0.24
Free Cash Flow-12.80-8.52-8.35-8.21-8.01--4.35-2.79-1.61
Preferred Dividends (Cash Flow)-0.000.000.000.00-0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments4.2010.270.601.722.070.75
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.170.150.100.110.170.21
Total Current Assets4.3710.420.701.832.230.96
Net Property, Plant & Equipment0.050.060.060.070.080.09
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets2.042.042.042.042.042.04
Other Assets0.000.000.000.330.000.43
Total Assets6.4612.522.804.274.363.52
Short Term Debt Incl. Current Port. of LT Debt0.040.700.650.910.830.04
Accounts Payable1.304.043.043.874.842.51
Other Current Liabilities0.111.090.360.080.040.26
Total Current Liabilities1.465.834.044.865.712.80
Long Term Debt0.010.020.030.040.050.06
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities1.465.854.074.905.762.86
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.006.67-1.27-0.63-1.410.65
Total Shareholders Equity5.006.67-1.27-0.63-1.410.65
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.006.67-1.27-0.63-1.410.65
Total Liabilities & Stockholders Equity6.4612.522.804.274.363.52
Book Value Per Share10.7468.55-17.01-10.99-53.8932.19
Tangible Book Value Per Share6.3647.60-44.28-46.38-132.04-68.48
Full-Time Employees--7---
Price to Book Ratio0.201.00-1.94-11.28-6.654.40
Return on Assets-234.30-167.97-343.49-219.08-165.62-140.10
Return on Equity-705.71-367.70-1,625.11-436.14-356.46-190.70
Return on Invested Capital-48.50-44.22----333.61
Quick Ratio3.001.790.170.380.390.34
Current Ratio3.001.790.170.380.390.34

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-2.41-2.96-4.17-3.31-3.43-2.37
Other Funds (Non Cash)0.550.641.780.470.230.20
Funds from Operations-1.86-2.32-2.38-2.84-3.20-2.17
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.161.12-0.54-0.842.610.58
Cash from Operating Activities-5.01-1.19-2.92-3.68-0.59-1.60
Capital Expenditures0.000.000.26-0.260.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.00-0.060.000.000.00
Purchase of Investments0.000.00-0.260.000.000.00
Sale Or Maturity of Investments0.000.000.190.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.20-0.260.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.1410.271.753.611.120.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.1410.271.753.611.120.00
Proceedsfrom Stock Options0.1410.031.753.471.120.00
Issuance or Reduction of Debt, Net-1.240.59-0.170.010.760.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-1.1010.861.583.621.880.00
Exchange Rate Effect0.020.00-0.00-0.040.020.00
Net Change in Cash-6.099.67-1.15-0.361.31-1.59
Free Cash Flow-5.01-1.19-2.92-3.68-0.59-1.60

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-305.04%0.0M0.6M477.71K
2026-10-156.32%0.0M0.6M474.35K
2026-09-308.39%0.0M0.6M478.41K
2026-09-154.10%0.0M0.6M52.28K
2026-08-317.33%0.0M0.5M50.80K
2026-08-141.86%0.0M0.5M126.09K
2026-07-313.97%0.0M0.4M124.97K
2026-07-154.97%0.0M0.4M188.66K
2026-06-305.83%0.0M0.4M198.82K
2026-06-154.07%0.0M0.4M476.88K
2026-05-296.91%0.0M0.4M478.60K
2026-05-151.79%0.0M0.2M390.24K
2026-04-307.53%0.0M0.1M379.46K
2026-04-1530.24%0.0M0.1M319.41K
2026-03-3167.56%0.1M0.1M310.73K
2026-03-135.34%0.0M0.1M2.79K
2026-02-272.52%0.0M0.1M17.64K
2026-02-132.51%0.0M0.1M17.66K
2026-01-305.49%0.0M0.1M23.59K
2026-01-156.17%0.0M0.1M23.31K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-098-KCurrent report2026-10-09SEC
2026-08-278-KCurrent report2026-08-26SEC
2026-08-2010-Q/A2026-06-30SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-214Statement of changes in beneficial ownership of securities2026-07-17SEC
2026-07-178-KCurrent report2026-07-17SEC
2026-07-16DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-16DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-02DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-22PRER14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-05ARSAnnual report to security holders. 2025-12-31SEC
2026-06-05DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-06-05DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-17SEC
2026-05-278-KCurrent report2026-05-26SEC
2026-05-26PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-07-17SEC
2026-05-26424B5SEC
2026-05-19EFFECTEffectiveness filing by commission orderSEC
2026-05-18424B5SEC
2026-05-15CORRESPSEC
2026-05-158-KCurrent report2026-05-11SEC
2026-05-15SCHEDULE 13GSEC
2026-05-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-14S-3/ASEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
UBS Group AG2.38%
JANE STREET GROUP, LLC1.90%
CITIGROUP INC0.65%
GEODE CAPITAL MANAGEMENT, LLC0.40%
StoneX Group Inc.0.36%
VANGUARD CAPITAL MANAGEMENT LLC0.29%
Tower Research Capital LLC0.24%
VANGUARD FIDUCIARY TRUST CO0.09%
ROTHSCHILD INVESTMENT LLC0.00%
TD Waterhouse Canada Inc.0.00%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.29%
Fidelity Extended Market Index Fund0.03%
Fidelity Nasdaq Composite Index Fund0.01%
Fidelity Series Total Market Index Fund0.00%

OakChart. ARTL. Cached 15 minutes.

Some panels did not load: insider.